Cargando…

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

Detalles Bibliográficos
Autor principal:	Kalantari, H Rezaei
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768102/ https://www.ncbi.nlm.nih.gov/pubmed/19755985 http://dx.doi.org/10.1038/sj.bjc.6605303

Ejemplares similares

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2009)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
por: Di Fiore, F, et al.
Publicado: (2011)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort
por: Liu, Yun, et al.
Publicado: (2021)

A pilot study of assessing whole genome sequencing in newborn screening in unselected children in China
por: Jian, Min, et al.
Publicado: (2022)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma
por: Lamarca, A, et al.
Publicado: (2012)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist
por: Gole, Prachi, et al.
Publicado: (2014)

An Interesting Case: Sunitinib-Induced Microangiopathic Hemolytic Anemia and Nephrotic Syndrome
por: Haksöyler, Veysel, et al.
Publicado: (2021)

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Porta, C
Publicado: (2010)

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Charbonneau, C, et al.
Publicado: (2010)

Toxic renal injury at a glance
por: Gheshlaghi, Farzad
Publicado: (2012)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report
por: Takasaki, Shinya, et al.
Publicado: (2017)

Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats
por: Nasri, Hamid
Publicado: (2013)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Coppin, Chris
Publicado: (2010)

Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma
por: Domagała-Haduch, Małgorzata, et al.
Publicado: (2016)

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
por: Coelho, Rafael Corrêa, et al.
Publicado: (2016)

Several factors can alter the QTc interval in patients with end-stage renal disease
por: Gülgün, Mustafa
Publicado: (2016)

Severe hyperlactatemia in unselected surgical patients: retrospective analysis of prognostic outcome factors
por: Spiegelberg, Julia, et al.
Publicado: (2022)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma
por: Mizuno, Ryuichi, et al.
Publicado: (2017)

Influenza and anosmia: Important prediction factors for severity and death of COVID-19
por: Kim, Doo Hwan, et al.
Publicado: (2021)

Povidone-iodine toxicity in a child posted for laparoscopic removal of hepatic and renal hydatid cysts
por: Kaur, Gurpreet, et al.
Publicado: (2015)

Clinical predictive factors and prediction models for end‐stage renal disease in Chinese patients with type 2 diabetes mellitus
por: Gao, Yueming, et al.
Publicado: (2023)

Continuous ambulatory peritoneal dialysis: experience with 22 unselected patients with renal failure.
por: Finkelstein, F. O., et al.
Publicado: (1981)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mjtjvbe6dmvr4o4iv4ci9nrck9